Evolocumab reduced LDL-C levels by @ % ( @ % CI , @ % to @ % ) to @ % ( @ % CI , @ % to @ % ) ( every @ weeks ) and by @ % ( @ % CI , @ % to @ % ) to @ % ( @ % CI , @ % to @ % ) ( monthly ) vs placebo at the mean of weeks @ and @ in the moderate - and high-intensity statin-treated groups ; the LDL-C reductions at week @ were comparable .